Literature DB >> 20942815

Critical role of the STAT3 pathway in the cardioprotective efficacy of zoniporide in a model of myocardial preservation - the rat isolated working heart.

L Gao1, J Tsun, L Sun, J Kwan, A Watson, P S Macdonald, M Hicks.   

Abstract

BACKGROUND AND
PURPOSE: Ischemia-reperfusion injury plays an important role in the development of primary allograft failure after heart transplantation. Inhibition of the Na+/H+ exchanger is one of the most promising therapeutic strategies for treating ischemia-reperfusion injury. Here we have characterized the cardioprotective efficacy of zoniporide and the underlying mechanisms in a model of myocardial preservation using rat isolated working hearts. EXPERIMENTAL APPROACH: Rat isolated hearts subjected to 6 h hypothermic (1-4°C) storage followed by 45 min reperfusion at 37°C were treated with zoniporide at different concentrations and timing. Recovery of cardiac function, levels of total and phosphorylated protein kinase B, extracellular signal-regulated kinase 1/2, glycogen synthase kinase-3β and STAT3 as well as cleaved caspase 3 were measured at the end of reperfusion. Lactate dehydrogenase release into coronary effluent before and post-storage was also measured. KEY
RESULTS: Zoniporide concentration-dependently improved recovery of cardiac function after reperfusion. The functional recovery induced by zoniporide was accompanied by up-regulation of p-extracellular signal-regulated kinase 1/2 and p-STAT3, and by reduction in lactate dehydrogenase release and cleaved caspase 3. There were no significant differences in any of the above indices when zoniporide was administered before, during or after ischemia. The STAT3 inhibitor, stattic, abolished zoniporide-induced improvements in functional recovery and up-regulation of p-STAT3 after reperfusion. CONCLUSIONS AND IMPLICATIONS: Zoniporide is a potent cardioprotective agent and activation of STAT3 plays a critical role in the cardioprotective action of zoniporide. This agent shows promise as a supplement to storage solutions to improve preservation of donor hearts.
© 2011 The Authors. British Journal of Pharmacology © 2011 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20942815      PMCID: PMC3041253          DOI: 10.1111/j.1476-5381.2010.01071.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  61 in total

1.  Cardioprotection by cariporide after prolonged hypothermic storage of the isolated working rat heart.

Authors:  Jonathan Rhys David Cropper; Mark Hicks; Jonathon Bruce Ryan; Peter Simon Macdonald
Journal:  J Heart Lung Transplant       Date:  2003-08       Impact factor: 10.247

2.  The NHE1 Na+/H+ exchanger recruits ezrin/radixin/moesin proteins to regulate Akt-dependent cell survival.

Authors:  Karen L Wu; Shenaz Khan; Sujata Lakhe-Reddy; George Jarad; Amitava Mukherjee; Carlos A Obejero-Paz; Martha Konieczkowski; John R Sedor; Jeffrey R Schelling
Journal:  J Biol Chem       Date:  2004-04-19       Impact factor: 5.157

3.  Platelet-derived growth factor induces phosphorylation of multiple JAK family kinases and STAT proteins.

Authors:  M L Vignais; H B Sadowski; D Watling; N C Rogers; M Gilman
Journal:  Mol Cell Biol       Date:  1996-04       Impact factor: 4.272

4.  Na+/H+ exchanger inhibitor HOE-642 improves cardioplegic myocardial preservation under both normothermic and hypothermic conditions.

Authors:  A R Shipolini; M Galiñanes; S J Edmondson; D J Hearse; M Avkiran
Journal:  Circulation       Date:  1997-11-04       Impact factor: 29.690

5.  Experimental evaluation of Celsior, a new heart preservation solution.

Authors:  P Menasché; J L Termignon; F Pradier; C Grousset; C Mouas; G Alberici; M Weiss; A Piwnica; G Bloch
Journal:  Eur J Cardiothorac Surg       Date:  1994       Impact factor: 4.191

6.  A rapid ischemia-induced apoptosis in isolated rat hearts and its attenuation by the sodium-hydrogen exchange inhibitor HOE 642 (cariporide).

Authors:  S Chakrabarti; A N Hoque; M Karmazyn
Journal:  J Mol Cell Cardiol       Date:  1997-11       Impact factor: 5.000

7.  Amiloride enhances postischemic ventricular recovery: possible role of Na+-H+ exchange.

Authors:  M Karmazyn
Journal:  Am J Physiol       Date:  1988-09

8.  Cariporide (HOE642), a selective Na+-H+ exchange inhibitor, inhibits the mitochondrial death pathway.

Authors:  Yasushi Teshima; Masaharu Akao; Steven P Jones; Eduardo Marbán
Journal:  Circulation       Date:  2003-10-20       Impact factor: 29.690

9.  Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK.

Authors:  Lindsey A Allan; Nick Morrice; Suzanne Brady; Gareth Magee; Shalini Pathak; Paul R Clarke
Journal:  Nat Cell Biol       Date:  2003-07       Impact factor: 28.824

10.  Cardioprotective efficacy of zoniporide, a potent and selective inhibitor of Na+/H+ exchanger isoform 1, in an experimental model of cardiopulmonary bypass.

Authors:  Hugh Clements-Jewery; Fiona J Sutherland; Mary C Allen; W Ross Tracey; Metin Avkiran
Journal:  Br J Pharmacol       Date:  2004-03-22       Impact factor: 8.739

View more
  9 in total

1.  Achieving 12 Hour Normothermic Ex Situ Heart Perfusion: An Experience of 40 Porcine Hearts.

Authors:  John M Trahanas; Lucas J Witer; Fares Alghanem; Benjamin S Bryner; Amit Iyengar; Jacob R Hirschl; Mark J Hoenerhoff; Joseph A Potkay; Robert H Bartlett; Alvaro Rojas-Pena; Gabe E Owens; Martin L Bocks
Journal:  ASAIO J       Date:  2016 Jul-Aug       Impact factor: 2.872

2.  Intralipid protects the heart in late pregnancy against ischemia/reperfusion injury via Caveolin2/STAT3/GSK-3β pathway.

Authors:  Jingyuan Li; Gregoire Ruffenach; Georgios Kararigas; Christine M Cunningham; Negar Motayagheni; Neusha Barakai; Soban Umar; Vera Regitz-Zagrosek; Mansoureh Eghbali
Journal:  J Mol Cell Cardiol       Date:  2016-11-12       Impact factor: 5.000

Review 3.  DCD donations and outcomes of heart transplantation: the Australian experience.

Authors:  Kumud Dhital; Prakash Ludhani; Sarah Scheuer; Mark Connellan; Peter Macdonald
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2020-08-15

4.  Tagging of genomic STAT3 and STAT1 with fluorescent proteins and insertion of a luciferase reporter in the cyclin D1 gene provides a modified A549 cell line to screen for selective STAT3 inhibitors.

Authors:  Andrey Samsonov; Nathan Zenser; Fan Zhang; Hongyi Zhang; John Fetter; Dmitry Malkov
Journal:  PLoS One       Date:  2013-07-09       Impact factor: 3.240

5.  Primary graft failure after heart transplantation.

Authors:  Arjun Iyer; Gayathri Kumarasinghe; Mark Hicks; Alasdair Watson; Ling Gao; Aoife Doyle; Anne Keogh; Eugene Kotlyar; Christopher Hayward; Kumud Dhital; Emily Granger; Paul Jansz; Roger Pye; Phillip Spratt; Peter Simon Macdonald
Journal:  J Transplant       Date:  2011-08-01

Review 6.  Non-Heart-Beating Donor Heart Transplantation: Breaking the Taboo.

Authors:  Javid Fatullayev; Mostafa Samak; Anton Sabashnikov; Alexander Weymann; Prashant N Mohite; Diana García-Sáez; Nikhil P Patil; Pascal M Dohmen; Aron-Frederik Popov; Andre R Simon; Mohamed Zeriouh
Journal:  Med Sci Monit Basic Res       Date:  2015-07-15

7.  Functional recovery after dantrolene-supplementation of cold stored hearts using an ex vivo isolated working rat heart model.

Authors:  Jeanette E Villanueva; Ling Gao; Hong C Chew; Mark Hicks; Aoife Doyle; Min Ru Qui; Kumud K Dhital; Peter S Macdonald; Andrew Jabbour
Journal:  PLoS One       Date:  2018-10-12       Impact factor: 3.240

8.  The Effect of Increasing Donor Age on Myocardial Ischemic Tolerance in a Rodent Model of Donation After Circulatory Death.

Authors:  Jeanette E Villanueva; Hong C Chew; Ling Gao; Aoife Doyle; Sarah E Scheuer; Mark Hicks; Andrew Jabbour; Kumud K Dhital; Peter S Macdonald
Journal:  Transplant Direct       Date:  2021-05-18

Review 9.  Transplantation of Hearts Donated after Circulatory Death.

Authors:  Christopher W White; Simon J Messer; Stephen R Large; Jennifer Conway; Daniel H Kim; Demetrios J Kutsogiannis; Jayan Nagendran; Darren H Freed
Journal:  Front Cardiovasc Med       Date:  2018-02-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.